Uncategorized
Akorn acquires Betimol from Santen
Akorn has acquired the new drug application for and all rights to Betimol from Santen, according to a press release. Akorn intends to begin distribution of Betimol (timolol ophthalmic solution 0.25% and 0.5%) in the first quarter of this year. The transaction is expected to add $8 million to $9 million in revenues and $0.03 to $0.04 of adjusted net income per diluted share for Akorn in 2014, the release said.